Neuropathic Pain in Long COVID Impacts COVID Symptom Prevalence and QOL

Publication date: Dec 19, 2024

They used the Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) to categorize pain as neuropathic or non-neuropathic. Criteria for a diagnosis of long COVID were the presence of new, recurrent, or ongoing health problems 3 months after their initial SARS-CoV-2 infection. The NeuroQoL evaluates physical, mental, and social effects of living with neurologic conditions and was used in the current study to assess cognitive impairment. The EQ VAS, with values ranging from 0 to 100 (best to worst health imaginable) provides a broad assessment of health quality. The researchers assessed QOL measures using the EuroQoL Visual Analog Scale (EQ VAS) and Quality of Life in Neurological Disorders (NeuroQoL) scales.

Concepts Keywords
Covid Confusion
Fatigue Covid
Swings Found
Tumor Long
Muscle
Neuropathic
New
Non
Pain
Prevalence
Qol
Reported
Symptoms
Weakness
Years

Semantics

Type Source Name
disease MESH confusion
disease MESH SARS-CoV-2 infection
disease IDO symptom
disease MESH Long COVID
disease MESH Neuropathic Pain
pathway REACTOME SARS-CoV-2 Infection
disease IDO quality
pathway REACTOME Release
disease IDO process
disease IDO history
disease MESH Neurological Disorders
disease MESH cognitive impairment
disease MESH brain fog
disease MESH shortness of breath

Original Article

(Visited 1 times, 1 visits today)